insights into the enhance-3 study: azacitidine plus venetoclax with or without magrolimab in aml
Published 1 month ago • 74 plays • Length 2:14
Download video MP4
Download video MP3
Similar videos
-
2:26
enhance-2: phase iii study of magrolimab plus azacitidine in untreated tp53-mutant aml
-
2:11
update on phase i/ii study of azacitidine, venetoclax and gilteritinib in patients with flt3 aml
-
5:36
venetoclax and azacitidine in mds patients
-
2:20
pevonedistat, azacitidine and venetoclax triplet therapy for aml, mds and cmml
-
1:31
azacitidine and venetoclax plus gilteritinib in the treatment of flt3-mutated aml
-
51:36
30. immunology 1 – diversity, specificity, & b cells
-
12:05
venetoclax combinations, safety and efficacy
-
15:13
how effective is venetoclax? #aml
-
3:15
developments in targeted aml therapies: venetoclax, quizartinib & gilteritinib
-
0:47
overview of the phase iii enhance trial schema
-
2:49
improving the activity of bh3 mimetic venetoclax: a case study
-
1:19
insights into a phase i/ia study of venetoclax, ixazomib and dexamethasone for r/r al amyloidosis
-
1:59
phase i study of pevonedistat, azacitidine, and venetoclax in patients with r/r aml
-
2:33
a retrospective study assessing ven-aza versus aza alone for treating aml in first relapse
-
3:52
venetoclax & aml
-
1:07
an insight into the pathogenesis of aml
-
4:03
a phase i/ii study evaluating quizartinib plus decitabine and venetoclax in flt3-mutated aml
-
6:50
an overview of the immunotherapy landscape in aml: antibodies, bispecifics, & car-t
-
3:24
novel agents in higher-risk mds
-
1:18
beat aml master sub-study: enasidenib and response-driven addition of azacitidine in idh2m aml
-
1:29
the current landscape of maintenace therapy in aml and areas for future exploration
-
2:18
what's special about immunology? an insight into the mission and vision of the journal
Clip.africa.com - Privacy-policy